Compare State Street SPDR S&P Biotech ETF (XBI) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Clear Secure Inc — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.93, while Clear Secure Inc trades at $43.42 (market cap $4.49B). The key difference: Clear Secure Inc pays a 1.32% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Clear Secure Inc nearer its low. Which is the better fit depends on your goals.
| XBI | YOU | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $169.55 | $62.36 |
52-Week Low | $93.43 | $29.61 |
Market Cap | — | $4.49B |
Enterprise Value | — | $3.64B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Clear Secure (YOU) trades at $43.6, down 1.65% on the day, amid a bearish technical signal. The company shows strong fundamental momentum with 27% year-over-year revenue growth in Q2 2026 and expanding profitability, though valuation ratios like a P/E of 29.46 appear elevated. Recent news highlights a strategic partnership with CrowdStrike and the launch of corporate memberships, signaling growth initiatives beyond airports.
The outlook is mixed: robust earnings beats and membership growth support upside, but high valuation and insider selling pose risks. Analyst consensus is evenly split between Buy and Hold, reflecting cautious optimism. Key near-term catalysts include Q3 2026 earnings and the success of new enterprise offerings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
